Zynerba Pharmaceuticals Inc

Zynerba Pharmaceuticals — Investor Presentation (May 2021)

26 slides from Zynerba Pharmaceuticals's investor presentation, May 5, 2021

  1. Slide 1: Corporate Overview May 2021

    PHARMACEUTICALS Advancing Science | Improving Connections Corporate Overview May 2021

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements THE STATEMENTS IN THIS PRESENTATION MAY INCLUDE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. THESE STATEMENTS, AMONG OTHER THINGS RELATE TO THE FUTURE OPERATIONS, OPPORTUNITIES OR FINANCIAL PERFORMANCE OF ZYNERBA PH

  3. Slide 3: A Rare/Near-Rare Neuropsychiatric Company

    3 A Rare/Near-Rare Neuropsychiatric Company Deep pipeline targeting high unmet medical needs; translating into multi-billion dollar market opportunity with Zygel™ (Cannabidiol Gel) Focused on initiating RECONNECT trial of Zygel in Fragile X syndrome (FXS) in Q3 2021 Continuing to pursue three additi

  4. Slide 4: Deep Clinical Pipeline & Zygel Cannabidiol Gel

    Deep Clinical Pipeline & Zygel Cannabidiol Gel **Orphan Drug designation 4 Indication Preclinical Phase 1 Phase 2 Pivotal Expected Milestones Fragile X Syndrome (FXS)* Initiate confirmatory RECONNECT pivotal trial in Q3 2021 Screening of patients has resumed; timing for top line results TBD when enr

  5. Slide 5: Zygel (ZYN002) Cannabidiol Gel

    Zygel (ZYN002) Cannabidiol Gel Differentiated Transdermal Unique Mechanism Neuropsych Indications of Action First & only patent-protected (2038), permeation-enhanced, pharmaceutically-produced cannabidiol gel Formulation delivers Cannabidiol through the epidermis and into the circulatory system Cann

  6. Slide 6: Fragile X Syndrome (FXS)

    FXS is routinely diagnosed by assessing (1) CGG repeats and (2) methylation status *FMR Protein; RNA-binding protein that helps regulate synaptic development and plasticity 6 Fragile X Syndrome (FXS) FXS Rare genetic developmental disability Leading known cause of both inherited intellectual disabil

  7. Slide 7: CONNECT-FX Trial Design

    *Patients with complete methylation of their FMR1 gene (137 total ~ 65% of trial population) 7 CONNECT-FX Trial Design Clinical study Of CaNNabidiol in ChildrEn and AdolesCenTs with Fragile X (CONNECT-FX) Zygel (n=110; 72*) 250 mg daily 500 mg daily (weight-based dose) Placebo (n=102; 65*) Mirrored

  8. Slide 8: Endpoints and Data Collected

    8 Endpoints and Data Collected Primary endpoint: Change from baseline to end of treatment in ABC-CFXS Social Avoidance subscale Key secondary endpoints: Change from baseline to end of the treatment in ABC-CFXS Irritability subscale score ABC-CFXS Socially Unresponsive/Lethargic subscale score Improv

  9. Slide 9: CONNECT-FX Results: Complete FMR1 Methylation

    CONNECT-FX Results: Complete FMR1 Methylation Consistent Improvements Observed with Zygel vs. Placebo ABC-CFXS Social Avoidance subscale Caregiver Global Impression of Change 40% median percent improvement in socially avoidant behaviors (p=0.027*) Clinically meaningful improvement on drug Significan

  10. Slide 10: Zygel was very well tolerated

    10 Zygel was very well tolerated No serious or severe adverse events reported during the trial All treatment-emergent adverse events (TEAEs; any event, whether unrelated or related to study drug) were mild or moderate Most common treatment-related TEAE: application site pain Zygel: 6.4%; placebo: 1.

  11. Slide 11: RECONNECT Trial Design

    *Patients with complete (100%) methylation of the FMR1 gene 11 RECONNECT Trial Design Randomized, Double-Blind, Placebo-Controlled, Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents with Fragile X Syndrome Zygel (n~100; 80*) 250 mg dai

  12. Slide 12: RECONNECT Trial Design: Endpoints and Changes

    and skin diaries 12 RECONNECT Trial Design Primary endpoint will be change vs. placebo in Social Avoidance subscale of ABC-CFXS for children and adolescents who have complete (100%) methylation of the FMR1 gene Partial methylation cohort will have descriptive statistics gathered and they will be com

  13. Slide 13: Autism Spectrum Disorder (ASD)

    Autism Spectrum Disorder (ASD) ASD Results from clinical trials of Zygel suggest spectrum of activity against core behaviors Newer studies suggest ASD is linked to disruption of the ECS Altered anandamide signaling may contribute to ASD-related social and communication impairments ECS system modulat

  14. Slide 14: BRIGHT Phase 2 Trial in ASD

    BRIGHT Phase 2 Trial in ASD Open-LaBel ToleRabIlity and Efficacy Study of ZYN002 Administered as a Transdermal Gel to CHildren and AdolescenTs with Autism Spectrum Disorder Zygel 14 Weeks 14 weeks: COMPLETE 37 pts with moderate-to-severe ASD enrolled Three through 17 years of age 24 Weeks Open label

  15. Slide 15: Results of BRIGHT Phase 2 Trial

    Qualitative Caregiver Behavioral Problems Survey % Improvements Behavioral: 69% improved Social: 63% improved Emotional: 72% improved * Statistically significant Full data available in May 26, 2020 and October 15, 2020 press releases 15 ABC-C subscales % improvement Irritability: 39.1% (p<0.0001*) I

  16. Slide 16: Well Tolerated Safety Profile in BRIGHT Trial in ASD

    16 Well Tolerated Safety Profile in BRIGHT Trial in ASD Well tolerated; consistent with previously released data Fewer than half of patients experienced an adverse event (AE); most were mild and transient Only 14% of patients experienced a treatment-related AE All application site-related No severe

  17. Slide 17: Next Steps in ASD Program

    17 Next Steps in ASD Program In 1H2021, Zynerba intends to discuss data supporting the potential efficacy of Zygel in ASD, including the results of the Phase 2 BRIGHT trial, with the FDA to determine the regulatory path forward Present additional data at future medical meetings

  18. Slide 18: 22q11.2 Deletion Syndrome (22q)

    22q11.2 Deletion Syndrome (22q) 22q Rare disorder; most common contiguous gene deletion syndrome Midline condition with abnormalities affecting palate, face, heart and other organs; surgically corrected in infancy Neuropsychiatric illnesses (anxiety disorders, ASD) and learning disabilities common 2

  19. Slide 19: INSPIRE Phase 2 Trial in 22q

    Clinical Global Impression – Severity and Improvement 19 INSPIRE Phase 2 Trial in 22q Assessing the Impact of Zygel (Transdermal Cannabidiol Gel) on Pediatric Behavioral and Emotional Symptoms of 22q11.2 Deletion Syndrome Zygel 14 Weeks 14 Weeks Target: 20 patients Six through 17 years of age 24 Wee

  20. Slide 20: Developmental and Epileptic Encephalopathies (DEE)

    20 Developmental and Epileptic Encephalopathies (DEE) DEE Group of rare / ultra rare childhood-onset epilepsies with impaired or regressed developmental progress Cognitive impairment, psychiatric problems, and behavioral disturbances are phenotypic Medically fragile population Comorbidities include

  21. Slide 21: BELIEVE Phase 2 Trial in DEE

    21 BELIEVE Phase 2 Trial in DEE Open LaBel Study to Assess the Safety and Efficacy of ZYN002 Administered as a TransdermaL Gel to ChIldren and AdolEscents with DeVelopmental and Epileptic Encephalopathy Maintenance 22 Weeks Titration 4 Weeks Six months: COMPLETE 48 patients enrolled Three through 17

  22. Slide 22: Results of BELIEVE Phase 2 Trial

    Sleep Disturbance Scale for Children (SDSC) % Improvement Statistically significant improvements observed in Total Score: 36%; p=0.012 Disorders of initiating/maintaining sleep: 22%; p=0.006 Disorders of arousal/nightmares: 100%; p=0.031 Sleep wake transition disorder: 31%; p=0.030 Full data availab

  23. Slide 23: Zygel Well Tolerated over months: No Safety Signal Identified

    23 Zygel Well Tolerated over 12 months: No Safety Signal Identified Tolerability profile consistent with the safety database for Zygel Most treatment-emergent adverse events (TEAEs) (any event, whether unrelated or related to study drug) were mild or moderate Two SAEs deemed possibly drug-related (L

  24. Slide 24: Clean balance sheet

    24 Clean balance sheet No debt, 41.3 M shares outstanding (as of March 5, 2020) Cash and cash equivalent position of $59.2M as of December 31, 2020 From January 1, 2021 to February 9, 2021 we raised net proceeds of $42.2 million through the sale of 10.2 million shares of equity through our “At The M

  25. Slide 25: Deep Clinical Pipeline & Zygel Cannabidiol Gel

    Deep Clinical Pipeline & Zygel Cannabidiol Gel **Orphan Drug designation 25 Indication Preclinical Phase 1 Phase 2 Pivotal Expected Milestones Fragile X Syndrome (FXS)* Initiate confirmatory RECONNECT pivotal trial in Q3 2021 Screening of patients has resumed; timing for top line results TBD when en

  26. Slide 26: Corporate Overview May 2021

    PHARMACEUTICALS Advancing Science | Improving Connections Corporate Overview May 2021

Zynerba Pharmaceuticals — Investor Presentation (May 2021) on 6ix